Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression

Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression

Hepatocellular carcinoma (HCC) remains a notably global health challenge with high mortality rates and poor prognosis. The deregulation of the Hippo signalling pathway, especially the overexpression and activation of downstream effector Yes-associated protein (YAP), has been demonstrated to result i...

Full description

Bibliographic Details
Main Authors: Du Jiamin, Qian Meijia, Yuan Tao, Zhang Bo, Chen Xueqin, An Ning, He Qiaojun, Yang Bo, Ye Song, Zhu Hong
Format: Article
Language:English
Published: Sciendo 2022-09-01
Series:Acta Pharmaceutica
Subjects:
fingolimod
hepatocellular carcinoma
hippo signalling
yap/taz
Online Access:https://doi.org/10.2478/acph-2022-0029

Internet

https://doi.org/10.2478/acph-2022-0029

Similar Items